Published in J Virol on January 01, 1988
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol (1996) 5.59
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A (1989) 4.26
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 3.92
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol (1988) 3.88
Genetic recombination of human immunodeficiency virus. J Virol (1989) 3.61
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Mutational analysis of the human immunodeficiency virus vpr open reading frame. J Virol (1989) 3.48
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol (1989) 3.36
Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J (1998) 3.30
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol (1991) 3.05
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood (2008) 2.96
Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol (1992) 2.88
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
Role of the DIS hairpin in replication of human immunodeficiency virus type 1. J Virol (1996) 2.87
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J Virol (1993) 2.69
Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol (1989) 2.62
Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol (1989) 2.60
The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol (1992) 2.49
Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys). J Virol (1995) 2.47
The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J Virol (1989) 2.46
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J (1989) 2.45
The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol (2011) 2.44
A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem (2009) 2.40
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A (1990) 2.32
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol (1993) 2.22
Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. J Virol (1990) 2.21
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol (2007) 2.03
Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A (1996) 2.02
Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol (1998) 2.01
Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIV (AGM). J Virol (1990) 1.99
Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol (1992) 1.94
Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization. J Virol (1992) 1.94
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J Virol (1994) 1.92
Molecular cloning of feline immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 1.92
A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication. J Virol (1997) 1.91
Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci U S A (1989) 1.89
Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol (1994) 1.88
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A (2003) 1.88
Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate. J Virol (1990) 1.86
Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1988) 1.86
Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A (1994) 1.84
Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol (1991) 1.83
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol (1990) 1.83
Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J Virol (1988) 1.82
Binding kinetics of ecotropic (Moloney) murine leukemia retrovirus with NIH 3T3 cells. J Virol (1995) 1.82
Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J (1988) 1.81
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81
Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity. EMBO J (1994) 1.78
Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci U S A (2005) 1.75
Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol (1991) 1.74
Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol (2009) 1.74
Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol (1994) 1.72
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71
Model for intracellular folding of the human immunodeficiency virus type 1 gp120. J Virol (1989) 1.70
Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest (1998) 1.70
Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection. J Virol (1995) 1.70
Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid. Nucleic Acids Res (2009) 1.69
Molecular structure of the cell-attachment protein of reovirus: correlation of computer-processed electron micrographs with sequence-based predictions. J Virol (1990) 1.69
Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol (1992) 1.68
HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci U S A (1996) 1.67
Mutational analysis of the N-linked glycosylation sites of the SU envelope protein of Moloney murine leukemia virus. J Virol (1992) 1.64
Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A (2006) 1.63
Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.61
Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 1.61
Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation. J Exp Med (1989) 1.59
Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells. J Virol (1991) 1.59
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Screening lambdagt recombinant clones by hybridization to single plaques in situ. Science (1977) 83.82
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proc Natl Acad Sci U S A (1979) 21.22
Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci U S A (1984) 17.51
Nucleotide sequence of the AIDS virus, LAV. Cell (1985) 16.81
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template. DNA (1984) 14.55
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol (1985) 13.99
EK2 derivatives of bacteriophage lambda useful in the cloning of DNA from higher organisms: the lambdagtWES system. Science (1977) 13.24
Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol (1981) 13.11
Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science (1986) 12.49
Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell (1987) 11.56
Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell (1987) 11.15
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
In vitro packaging of a lambda Dam vector containing EcoRI DNA fragments of Escherichia coli and phage P1. Gene (1977) 10.75
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature (1986) 10.62
pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell (1987) 9.29
Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell (1986) 9.01
Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A (1985) 8.53
Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol (1985) 7.35
Trypsin action on the growth of Sendai virus in tissue culture cells. 3. Structural difference of Sendai viruses grown in eggs and tissue culture cells. J Virol (1973) 5.64
Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J Immunol (1986) 5.31
The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses. Rev Infect Dis (1980) 4.61
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
Specific-primer-directed DNA sequencing. Anal Biochem (1986) 4.31
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
Use of unpurified synthetic deoxynucleotide primers for rapid dideoxynucleotide chain termination sequencing. DNA (1984) 2.96
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Molecular cloning and primary nucleotide sequence analysis of a distinct human immunodeficiency virus isolate reveal significant divergence in its genomic sequences. Proc Natl Acad Sci U S A (1986) 1.61
A cell membrane "gp70" associated with Fv-4 gene: immunological characterization, and tissue and strain distribution. Virology (1984) 1.32
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 32.58
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol (1985) 13.99
Base composition-independent hybridization in tetramethylammonium chloride: a method for oligonucleotide screening of highly complex gene libraries. Proc Natl Acad Sci U S A (1985) 13.19
Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature (1985) 12.08
Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol (1999) 11.77
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell (1987) 11.56
Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell (1987) 11.15
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature (1983) 10.64
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother (2000) 8.54
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 8.36
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Human serum activities against Hemophilus influenzae, type b. J Clin Invest (1972) 7.85
Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A (1982) 7.81
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Quantitation of Simian virus 40 sequences in African green monkey, mouse and virus-transformed cell genomes. J Mol Biol (1971) 7.10
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Comparative biochemical properties of normal and activated human ras p21 protein. Nature (1984) 6.50
A rapid chemical assay for gentamicin. N Engl J Med (1972) 6.36
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature (1984) 6.21
Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol (1987) 6.13
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature (1983) 5.90
In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol (1985) 5.77
Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications. Infect Immun (1980) 5.68
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
Characterization of the human factor VIII gene. Nature (1984) 5.37
A rapid method for detecting and mapping homology between heterologous DNAs. Evaluation of polyomavirus genomes. J Biol Chem (1979) 5.32
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
Comparison of phenotypic and genotypic techniques for identification of unusual aerobic pathogenic gram-negative bacilli. J Clin Microbiol (1998) 5.27
Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. Proc Natl Acad Sci U S A (1982) 5.25
Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature (1983) 5.25
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc Natl Acad Sci U S A (1989) 5.23
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Methylated nucleotides block 5'-terminus of vaccinia virus messenger RNA. Proc Natl Acad Sci U S A (1975) 5.16
Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity (1994) 5.06
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
A map of simian virus 40 transcription sites expressed in productively infected cells. J Mol Biol (1973) 5.02
Transferable R factors in enteric bacteria causing infection of the genitourinary tract. Lancet (1966) 5.01
Haemophilus influenzae meningitis in infant rats after intranasal inoculation. J Infect Dis (1974) 4.94
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol (1988) 4.92
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation. Infect Immun (1973) 4.80
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 4.72
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
R factors mediate resistance to mercury, nickel, and cobalt. Science (1967) 4.57
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene. Cell (1981) 4.42
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Expression of active human factor VIII from recombinant DNA clones. Nature (1984) 4.36
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J Cell Biol (1993) 4.34
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A (1989) 4.26
Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature (1983) 4.15
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
Identification and nucleotide sequence of a human locus homologous to the v-myc oncogene of avian myelocytomatosis virus MC29. Nature (1983) 4.06
Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (1984) 3.98
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations. J Virol (1983) 3.95
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene (1983) 3.94
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology (1995) 3.87
Identification of the fusion peptide of primate immunodeficiency viruses. Science (1989) 3.83
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol (1991) 3.79
Marburg-virus disease in Kenya. Lancet (1982) 3.79